ARS Pharmaceuticals, Inc. (SPRY)
3.23
-0.13
(-3.87%)
USD |
NASDAQ |
Nov 20, 10:47
ARS Pharmaceuticals Cash from Investing (Quarterly) : 23.41M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 23.41M |
| June 30, 2026 | 41.57M |
| March 31, 2026 | 27.79M |
| December 31, 2025 | 24.11M |
| September 30, 2025 | -44.98M |
| June 30, 2025 | 48.57M |
| March 31, 2025 | 29.06M |
| December 31, 2024 | -101.76M |
| September 30, 2024 | 16.82M |
| June 30, 2024 | -12.65M |
| March 31, 2024 | -8.513M |
| December 31, 2023 | 26.04M |
| September 30, 2023 | -46.64M |
| June 30, 2023 | 44.97M |
| Date | Value |
|---|---|
| March 31, 2023 | -111.55M |
| December 31, 2022 | 0.485M |
| September 30, 2022 | -0.03M |
| June 30, 2022 | -0.022M |
| March 31, 2022 | -0.021M |
| December 31, 2021 | 40.74M |
| September 30, 2021 | -40.06M |
| June 30, 2021 | -0.70M |
| March 31, 2021 | -0.035M |
| December 31, 2020 | -0.247M |
| September 30, 2020 | -0.632M |
| June 30, 2020 | -0.005M |
| March 31, 2020 | -0.033M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Capricor Therapeutics, Inc. | 59.90M |
| Sionna Therapeutics, Inc. | 38.95M |
| Ardelyx, Inc. | -54.00M |
| Zentalis Pharmaceuticals, Inc. | -55.31M |
| Compass Therapeutics, Inc. | 22.33M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -33.71M |
| Cash from Financing (Quarterly) | 27.76M |
| Free Cash Flow | -183.07M |
| Free Cash Flow Per Share (Quarterly) | -0.3382 |
| Free Cash Flow to Equity (Quarterly) | -58.84M |
| Free Cash Flow to Firm (Quarterly) | -31.16M |
| Free Cash Flow Yield | -56.54% |